SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

WorldFinancial

World Liberty Financial (WLFI) is a focal point of discussion due to a congressional probe into its $500 million investment with an Abu Dhabi entity and its ongoing application for a National Trust Bank Charter. This has sparked intense debate, with some community members forecasting substantial growth from its forthcoming real-world asset platform and app, while others strongly denounce it as a fraudulent scheme.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending after its swift decision to cease offering a compounded weight-loss pill following regulatory scrutiny and legal threats from major pharmaceutical companies. The community is divided, with some viewing it as a strategic de-risking move for its core telehealth business, while others criticize it as a major management blunder that damages trust and growth, amidst mixed reactions to its Super Bowl advertisement.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as record Super Bowl betting volume is anticipated, with community discussion intensely focused on how burgeoning prediction markets, operating under different regulatory frameworks, will impact its future profitability and market share amidst its own expansion into the evolving sector ahead of its impending earnings report.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending due to widespread discussions surrounding a potential future merger involving SpaceX and xAI, alongside recent announcements about high-volume Semi production and significant investments in AI, robotics, and autonomous driving. This is fueling bullish outlooks for its long-term vision, though the community also expresses concerns about near-term profitability and ongoing controversies related to its CEO.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors eagerly await its BLA resubmission in February, a key step validated by the FDA's request for the full HOPE-3 clinical study report without additional trials. This development reinforces confidence in its Duchenne muscular dystrophy therapy and promising exosome platform amidst discussions of institutional interest.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is trending following its recent acquisition and new financing designed to strengthen its HAE portfolio, yet community discussion remains largely negative, citing persistent stock undervaluation, increasing short interest, and perceived manipulation, further fueled by public comments from well-known financial personalities.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending amid a federal probe into alleged workplace discrimination and high anticipation for a Supreme Court ruling on tariffs that could impact its margins. While some in the community are betting on a strategic turnaround driven by new product innovation and North American growth, others remain skeptical, citing continued weakness in key markets.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is highly active, driven by mixed semiconductor earnings and strong underlying commitments to massive AI infrastructure spending from big tech. Community discussion centers on whether this leveraged ETF presents a 'buy the dip' opportunity given the persistent AI narrative, or if it's forming a triple top around current levels, signaling a potential reversal.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals is trending as strong Dupixent sales and recent pipeline breakthroughs in oncology and gene therapy are battling ongoing manufacturing delays for its Eylea HD pre-filled syringe at a third-party facility, prompting community discussion on the stock's undervaluation despite short-term volatility.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending following a recently announced $250 million financing amendment that extends its capital runway through 2028, fueling community speculation about a potential short squeeze and comparisons to its history of massive parabolic price movements. While many anticipate significant upward momentum, a notable counter-narrative raises concerns about potential dilution from the equity line of credit and the company's underlying profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Luke Evnin Sells 38,782 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 38,782 shares of the company's stock in a transaction on Friday, January 16th. The shares were sold at an average...

Luke Evnin Sells 30,616 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 30,616 shares of the company's stock in a transaction dated Wednesday, January 14th. The stock was sold at an...

Luke Evnin Sells 58,980 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 58,980 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of...

Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $11,761.92 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 18,378 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of...

Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 18,568 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 18,568 shares of the business's stock in a transaction on Friday, January 2nd. The shares were sold at an average...

Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $22,448.16 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 35,632 shares of the company's stock in a transaction dated Friday, December 26th. The stock was sold at an...

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 17,858 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 17,858 shares of the company's stock in a transaction dated Friday, December 12th. The shares were sold at an...

Luke Evnin Sells 37,104 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock in a transaction on Wednesday, December 10th. The stock was sold at...

Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $29,969.63 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock in a transaction dated Thursday, December 11th. The stock was sold at...

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.

Werewolf Therapeutics Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

Current Price	$0.6122
Prev Close	$0.606
Open	$0.649
Dividend Yield	0.00%
50-Day Moving Average	$0.7517
Beta	1.76
Avg. Volume	508,396.30
PE Ratio	-0.38

52-Week High	$2.38
52-Week Low	$0.5301
Market Capitalization	$29.72M
EPS (Annual)	-$1.63
Price to Book	0.98
Revenue Per Employee	$40,978.26
Enterprise Value/EBITDA	N/A

HOWL
Werewolf Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HOWL News

HOWLWerewolf Therapeutics Inc